Abstract:In order to construct a recombinant replication-deficient adenoviral vector, designated as AdsiSSF, which coexpresses a small hairpin human SOCS1-siRNA (siSOCS1), dominant negative (DN) survivin and MUC1 fusion protein, and a secretory flagellin, the TLR5 ligand (SupplementaryFig. 1A), we first modified survivin, MUC1, and flagellin genes, as well as identified siRNA that can effectively silence human SOCS1 (5’-CACGCACTTCCGCACATTC3’). Because of the anti-apoptotic biological activity of survivin for the potential promotion of malignant cell survival and transformation, two mutations were introduced into the survivin gene to generate a DN survivin mutant. A substitution mutation of Thr with Ala in position 34 was made to eliminate the p34-cyclin B1 phosphorylation site and anti-apoptotic activity, as described previously(1). Moreover, to avoid possible reverse mutation of the survivin mutant back to a functional phosphorylation site, a 16 amino acid truncation at the N-terminus of survivin was further made since the N-terminal sequence is required for its inhibition of apoptosis (2). We used a short human mucin 1 (MUC1) fragment containing only a three 20 amino acid tandem repeat sequence, because a known dominant T cell epitope is located within the 20 amino acid repeat(3)and full-length or lengthyMUC1 protein was found to have immune suppressive activity by inhibiting a Th1-type CTL response(4). To generate a DN survivinMUC1 fusion gene (DN SM) as target tumor-associated antigens for the Ad-siSSF vector, the double mutated DN survivin was genetically linked in-frame to the three 20 amino acid repeat fragment of MUC1. For facilitating the secretion and subsequent interaction with surface TLR5 on DCs of flagellin by transfected DCs, a signal leader sequence derived from human tyrosinase was genetically linked to the N-terminus of the flagellin gene. We also identified siRNA with the ability to specifically downregulate human SOCS1 (SupplementaryFig. 1B).

Primary Study on Preparation and Efficiency of Neotype Hepatocellular Carcinoma-dendritic Cell Vaccine with SOCS1 Expression Inhibited

Progress on Dendritic Cell Vaccines in Tumor Immunotherapy

Evaluation of human dendritic cell vaccine coexpressing a SOCS1 inhibitor, tumor-associated antigen, and TLR ligand

Efficacy of intracellular immune checkpoint-silenced DC vaccine

Effect of the Suppressors of Cytokine Signaling-1(Socs1) on the Differentiation and Maturation of Bone Marrow-Derived Dendritic Cells Induced by the TNF Superfamily Member LIGHT

A SOCS 1 antagonist enhances antigen-presenting capacity and tumor 1 cell antigen-specific cytotoxic T lymphocyte responses by human 2 monocyte-derived dendritic cells

Dendritic cells infected by Ad-sh-SOCS1 enhance cytokine-induced killer (CIK) cell immunotherapeutic efficacy in cervical cancer models

A Suppressor of Cytokine Signaling 1 Antagonist Enhances Antigen-Presenting Capacity and Tumor Cell Antigen-Specific Cytotoxic T Lymphocyte Responses by Human Monocyte-Derived Dendritic Cells

Silencing of SOCS1 Enhances Antigen Presentation by Dendritic Cells and Antigen-Specific Anti-Tumor Immunity

Effects of Epidermal Growth Factor Receptor Fusion Protein on the Cytotoxic Activity of SOCS1-silenced Dendritic Cells in Vitro

Single-component lipid nanoparticles for engineering SOCS1 gene-silenced dendritic cells to boost tumor immunotherapy

Interaction Between Member LIGHT of TNF Superfamily and SOCS3, Which Respond to Induce the Differentiation and Maturation of Dendritic Cell

Studies on the Enhancement of DC Vaccine to Mouse Lewis Lung Cancer by CpG Oligonucleotides

Enhanced Immunotherapeutic Effect of Modified HPV16 E7-pulsed Dendritic Cell Vaccine by an Adeno-Shrna-socs1 Virus

Expression Characteristics, Immune Signature, and Prognostic Value of the SOCS Family Identified by Multiomics Integrative Analysis in Liver Cancer

Suppression of Tumor Growth by Mrna DC Vaccine in Severe Combined Immune Deficiency Mouse

SOCS1 blocks G1-S transition in hepatocellular carcinoma by reducing the stability of the CyclinD1/CDK4 complex in the nucleus

Improvement of HBsAg gene-modified dendritic cell-based vaccine efficacy by optimizing immunization method or the application of β-glucosylceramide.

Efficacy of Intracellular Immune Checkpoint-SilencedDendritic Cell Vaccine

The Tumor Suppressor SOCS1 Diminishes Tolerance to Oxidative Stress in Hepatocellular Carcinoma

Enhanced Human T Lymphocyte Antigen Priming by Cytokine-Matured Dendritic Cells Overexpressing Bcl-2 and IL-12.